Aims/hypothesis. The aim of this study was to determine whether beta-cell autoimmunity is associated with immune response bias to exogenous antigens. Methods. IgG subclass responses against tetanus toxoid and rubella were measured after vaccination in children with (n=36) and without (n=73) islet autoantibodies participating in the BABYDIAB prospective study of offspring of parents with Type I (insulindependent) diabetes mellitus. All children had been vaccinated against tetanus toxoid antigen before 6 months of age and at 18 months of age, and against live attenuated rubella virus at 18 months of age and again before 5 years of age. Tetanus toxoid specific IgG subclasses and cytokine responses were compared in a second cohort of subjects. Results. Responses to tetanus toxoid in islet-autoantibody-negative children were characterized by early IgG1 antibodies at 9 months of age followed by the appearance of IgG4 and lesser IgG2 antibodies at 2 years of age. Children who had developed islet autoimmunity before one year of age (n=15) did not have the shift to IgG4 and IgG2 anti-TT after booster vaccination (p<0.01), and had undetectable or IgG1 restricted responses. This defect was independent of HLA class II genotype, was restricted to children who had islet autoimmunity before 1 year of age, and was most evident in children who already had multiple islet autoantibodies by 9 months of age. IgG4 and IgG2 anti-TT correlated with IL-4 (p<0.005), but not IFNγ responses. Antibody responses to the IFNγ-inducing rubella vaccination were strongly IgG1 dominated and no differences were observed between islet autoantibody positive and negative children. Conclusions/interpretation. These data are consistent with a reduced capacity to make IL-4 promoted antibody responses to exogenous antigen in early pre-diabetes. [Diabetologia (2002) 45:677-685] 
Autoimmune diabetes is a T-cell-mediated disease [1] . In animal models of the disease, autoimmunity is characterised by interferon-gamma (IFNγ) dominated immune responses to beta-cell autoantigens [2, 3, 4] , impaired regulatory mechanisms and reduced interleukin-4 (IL-4) responses which could lead to a generalized immune deviation [5, 6] .
In humans, evidence that Type I (insulin-dependent) diabetes mellitus is associated with a generalized skewing away from IL-4-mediated responses is provided by the observation that patients with Type I diabetes or autoimmunity to beta-cell antigens have a reduced prevalence of allergy [7, 8] . Another model to investigate generalized immune deviation is represented by the immune response to vaccination. Vaccination against both bacterial and viral infectious agents is done early in life on a large scale, representing an early environmental challenge to the immune system. The BABYDIAB study provided an opportunity to study immune responses to vaccine antigens with respect to diabetes risk. Children of parents with Type I diabetes are followed from birth with blood samples at 9 months, 2 years and 5 years of age [9] . Over 1500 children have been enrolled and 2.7% have developed persistent diabetes-associated islet autoantibodies [10] , making it possible to determine whether early beta-cell autoimmunity is associated with a general immune bias. As model antigens, tetanus and rubella were chosen for this study. Children were vaccinated against tetanus together with diphtheria and pertussis (DTP) bacterial antigens before 6 months of age with a subsequent booster at around 18 months of age, and the majority of children were also vaccinated with live attenuated rubella virus between age 1 and 2 years and then again before 5 years of age. Immune responses to the DTP bacterial antigens are expected to be mediated by both IFNγ and IL-4, whereas those against rubella are expected to be predominantly mediated by IFNγ. In the current study, antigen-specific antibody subclasses were used to measure the magnitude and quality of responses to these antigens. The subclass response is an indirect measure of T-cell phenotype in the mouse [11, 12] , while in humans IgG4 or IgE antibody production or both are promoted by the T helper (Th) 2 cytokines IL-4 and IL-13 [13, 14, 15, 16] . Our finding of a marked impairment in the IL-4 associated IgG4 response to tetanus toxoid (TT) in children with early established pre-diabetes supports the concept of a generalized immune deviation in the presence of beta-cell autoimmunity.
Methods and materials
Subjects. Serum samples used for measurement of TT antibodies in this study were obtained from the German BABYDIAB study [10] . BABYDIAB is a prospective study from birth in more than 1500 offspring of parents with Type I diabetes and regular blood sampling at birth, 9 months, 2, 5, and 8 years of age scheduled in all offspring. Offspring are tested for autoantibodies to insulin, GAD, the protein tyrosine phosphatase IA-2, and islet cells on all visits. At 2 years of age samples are also collected for HLA typing [17] . Of the 959 children followed until age 2 years, all have completed vaccination against TT, and of the 381 children followed until age 5 years, 285 have completed vaccination against rubella [18] . For this study, all children who had received tetanus or rubella vaccination and had developed persistent non-maternally acquired islet autoantibodies were included (Table 1) . Of these, 15 had developed islet autoantibodies already by 9 months of age (9 mo AutoAb+ offspring), and a further 21 were islet autoantibody negative at age 9 months but developed persistent islet autoantibodies at 2 years of age (2 yr AutoAb+ offspring). Thirteen of the islet autoantibody positive children have developed Type I diabetes between age 1.3 to 8.8 years. The high risk HLA DRB1* 03 DQB1*0201/DRB1*04 DQB1*0302 (DR3/4) or HLA DRB1* 04 DQB1*0302/DRB1*04 DQB1*0302 (DR4/4) genotypes were present in 16 of the islet autoantibody positive children. In order to control for potential HLA associated differences in the immune response to vaccination, all islet autoantibody-negative offspring with high risk genotypes (n=42) and 31 randomly selected autoantibody negative offspring without these genotypes were included for comparison in this study. None of the islet autoantibody negative children have developed Type I diabetes. DTP vaccination was given at around 3 months, 4 months, 5 months and 18 months of age in all but seven offspring (three autoantibody positive and four autoantibody negative) who received DT only at these time points. Antibodies to tetanus were measured in 9-month and 2-year serum samples. Measles, mumps and rubella (MMR) vaccination was given between 12 and 24 months of age followed by a booster vaccination before 5 years of age in 82 of the children included in this study. Antibodies to rubella antigen were measured in the 5-year samples from these children and from 20 offspring who were not vaccinated with MMR and had not reported rubella infection.
Both T-cell and antibody responses to TT were measured in a separate cohort of 31 subjects in whom samples could be obtained for T-cell studies. These 31 subjects included relatives from the BABYDIAB study and the Munich family study [19] in whom both T-cell and antibody studies could be performed at the same age. All subjects had completed vaccination against DTP. Subjects had a median age of 7.3 years, 24 had islet autoantibodies and 7 developed Type I diabetes.
Anti-vaccine Antibodies. IgG subclass antibodies to TT (anti-TT) were measured by an ELISA similar to that used in the World Health Organisation (WHO) evaluation of the WHO standard [20] . TT antigen used for antibody measurement was identical to that used in vaccine preparations. Flat bottom 96-well plates were coated with 0.5 LF/ml of TT antigen (Chiron Behring, Marburg, Germany) in 125 µl of 147 mmol/l NaCl, 1.5 mmol/l KCl, 2.7 mmol/l KH 2 PO 4 , 81 mmol/l Na 2 HPO 4, pH 7.4 (PBS) by overnight incubation at 4°C. Plates were washed three times in PBS containing 0.05% Tween 20 (PBST) and blocked in 0.1% gelatin in PBS. Sera were diluted 1/200 (total IgG), 1/800 (IgG1), and 1/400 (IgG2, IgG3, and IgG4) in PBST, 100 µl added to duplicate antigen coated wells and duplicate uncoated wells, and were incubated for 2 h at room temperature. Wells were washed two times with PBST and 100 µl of specific biotinylated monoclonal antibody to total IgG, IgG1, IgG2, IgG3 or IgG4 (Pharmingen, San Diego, Calif., USA) diluted 1/1000 in PBST were added. Plates were incubated for 2 h at room temperature, washed two times with PBST and 100 µl of peroxidase conjugated streptavidin (Pharmingen) diluted 1/1000 in PBST were added. After 1-h incubation, plates were washed three times with PBST, colour substrate (ABTS, Sigma-Aldrich, St Louis, Miss., USA) added, and the OD 405 of each well measured after 15 min incubation at room temperature. The OD of binding by sera to wells without antigen (median OD=0.33, range 0.31-0.35) was subtracted for each sample. IgG1 subclass anti-TT ODs were multiplied by two to allow for the two-fold higher serum dilution used in comparison to the remaining subclass measurements. Serial dilutions of the WHO reference standard were included in each assay to control for inter-assay variation. Dilutions showed linearity over the range of measurement. The interplate CVs for IgG1-, IgG2-, and IgG4-anti-TT were 4.3%, 5.6%, and 8.0%, respectively. Thresholds for IgG subclass anti-TT responses were determined using frequency histogram distributions and q-q plots [10] of all offspring results. For each subclass, the results showed a cohort with a normal distri-bution and for IgG1, IgG2, and IgG4 a second cohort with higher results. The upper range of the normal distributions corresponded to ODs of 0.3 for IgG1, 0.25 for IgG2, 0.15 for IgG3, and 0.10 for IgG4, and these were used as the threshold for indicating a specific antibody response. Validating these thresholds, the ODs of 20 sera from subjects who had not been vaccinated or did not have any IgG TT antibodies ranged from -0.03 to 0.27 for IgG1, 0.03 to 0.26 for IgG2, -0.11 to 0.08 for IgG3, and -0.02 to 0.08 for IgG4.
Human IgG subclass antibodies to Rubella-virus were measured by ELISA (Enzygnost Anti-Rubella-Virus/IgG, Dade Behring, Marburg, Germany). Sera were diluted 1/100 (IgG1) or 1/50 in PBST, 100 µl were added to duplicate wells coated with antigen (produced from a virus infected cell line) or control antigen (produced from an uninfected cell line), and were incubated for 2 h at room temperature. Wells were washed three times with PBST and 100 µl of specific biotinylated monoclonal antibody against human IgG1, IgG2, IgG3 and IgG4 (Pharmingen) diluted 1/500 in PBST were added. Wells were incubated for 2 h at room temperature, washed three times with PBST and 100 µl of 1/1000 dilution of peroxidase conjugated streptavidin (Pharmingen) added. After 1-h incubation, wells were washed three times with PBST, 100 µl of colour substrate (TMB Peroxidase Substrate Kit, Bio-Rad, Munich, Germany) added. After 10 min incubation at room temperature, 100 µl of 4 N H 2 SO 4 was added to stop the reaction and the OD 405 of each well measured. Results were obtained by subtracting OD of control antigen from OD of antigen. Package for Social Sciences (SPSS, Chicago, Ill., USA) was used. A p value of less than 0.05 (two-sided) was considered to be statistically significant.
Results

IgG subclass responses to tetanus vaccination in BABYDIAB offspring.
IgG subclass responses to TT in the BABYDIAB offspring were measured at both 9 months of age (after initial vaccination) and 2 years of age (after booster vaccination). At 9 months of age, 54% of all the children had anti-TT antibodies above thresholds for positivity (Fig. 1A) . Anti-TT antibody prevalence increased to 74% of all children at 2 years of age after booster vaccination. The predominant IgG subclass response at 9 months of age was IgG1. Low titres of IgG2 or IgG4 anti-TT or both were also found in a minority of offspring. At 2 years of age, IgG1 anti-TT antibodies remained at similar levels, IgG2 anti-TT titres increased slightly, whereas IgG4 anti-TT titres increased (p<0.001; Wilcoxon paired test). IgG1 anti-TT were found in 49 (47%), IgG2 anti-TT in 34 (33%) and IgG4 anti-TT in 68 (65%) of 104 offspring at 2 years of age. IgG3 anti-TT antibodies were not detected either at 9 months or 2 years of age. No dif- Anti-TT IgG subclass responses and islet autoimmunity. Both islet autoantibody positive and negative children had predominantly IgG1 anti-TT responses at 9 months of age (data not shown). However, at 2 years of age (after booster vaccination), significantly lower anti-TT responses were found in those offspring who were islet autoantibody positive already at age 9 months (Fig. 2) . In particular, the IgG4-anti-TT response did not rise in the 9 mo AutoAb+ offspring (median cOD 0.07; interquartile range 0-0.1) remaining at titres markedly lower than in the 2 yr AutoAb+ offspring (median cOD 0.34; interquartile range 0.12-0.85; p<0.01) and the AutoAb neg offspring (median cOD 0.31; interquartile range 0.06-0.74; p=0.02). Moreover, no IgG2-anti-TT response was detected in the 9 mo AutoAb+ offspring (p<0.001 vs 2 yr AutoAb+ and p<0.01 vs AutoAb neg), and IgG1 anti-TT were also low. Overall, IgG4 or IgG2 anti-TT or both above the threshold for positivity were found in only 2 (18%) of 11 9mo AutoAb+ offspring compared to 18 (82%) of 22 2 yr AutoAb+ offspring (p<0.001) and 50 (71%) of 70 AutoAb neg offspring (p<0.01). The reduced anti-TT responses were most obvious in the 4 offspring who had multiple islet autoantibodies already at 9 months of age. None of these had IgG2 or IgG4 anti-TT and only one had weak IgG1-anti-TT.
The reduced responses in the 9 mo AutoAb+ offspring were not due to HLA-associated differences in the anti-TT response: reduced IgG2 (p<0.01) and IgG4 (p<0.05) anti-TT antibodies in the 9 mo AutoAb+ offspring compared to the 2 yr AutoAb+ and AutoAb neg offspring were also observed if only children with HLA DR3/4 or DR4/4 genotypes were analysed (data not shown).
Antibody and T-cell responses to TT. T cells were not available in the majority of the BABYDIAB children. Therefore, in order to determine whether there was a relationship between TT antibody subclass responses and T cell cytokine phenotype, we correlated the cytokine profile of T cells after stimulation with TT and the IgG subclass of anti-TT antibodies in a separate cohort of 31 subjects (median age 7.3 years; 24 with islet autoantibodies). Utilizing ELISpot measurements, IL-4 and IL-13 responses to TT were strongly correlated (r=0.8, p<0.0001; Spearman's test; Fig. 3 ). Both IL-4 and IL-13 responses were moderately correlated with IFNγ responses (r=0.55, p<0.01; r=0.56, p<0.01, respectively). Ten subjects had relatively high IL-4 and IL-13 ELISpot responses to TT (all but one having also IFNγ responses), another 9 had IFNγ responses only and 12 had low or absent IFNγ, IL-4 and IL-13 responses to TT.
IgG4 anti-TT levels correlated with IL-4 responses to TT (r=0.55; p<0.002) and IL-13 responses (r=0.52; p<0.005), but not IFNγ responses (r=0.1). IgG2 anti-TT were similarly correlated with IL-4 (r=0.61; Fig. 2A-C. IgG1 (A), IgG2 (B) , and IgG4 anti-TT (C) antibodies in 2 years samples in 9 mo AutoAb+ offspring (n=11) compared to 2 yr AutoAb+ offspring (n=22) and AutoAb neg offspring (n=70).
• Offspring with islet autoantibodies against more than one autoantigen (insulin, GAD, or IA-2). IgG2 and IgG4 anti-TT titres were significantly decreased in 9 mo AutoAb+ offspring p<0.001) and IL-13 (r=0.47; p<0.01) and not IFNγ (r=0.1), whereas IgG1 anti-TT were not correlated with cytokine responses (data not shown). Accordingly, IgG2 and IgG4 anti-TT antibodies were higher in subjects with high IL-4 and IL-13 ELISpot TT responses (Fig. 4) than those with IFNγ only (p<0.05 for 
Antibody responses to Rubella vaccine antigen.
Rubella vaccine is a live attenuated virus, given in order to promote Th1 cytotoxic immunity to infection. Immunisation is given before 2 years of age and again before 5 years of age. We therefore examined antibody responses in 5-year samples from the BABY-DIAB offspring in order to determine whether the IgG subclass response of a predicted Th1 immunity differed to that against TT. Antibody responses to rubella were strongly IgG1 dominant (Fig. 5) . Almost all immunised children had raised IgG1 antibodies to rubella antigen and only a minority also had IgG2, IgG3, or IgG4 antibodies. Unlike the response to TT, IgG3 anti-rubella antibodies above levels found in nonimmunised children could be detected and IgG4 antirubella antibodies were only marginally higher than in non-immunised children. No differences in antibody responses to rubella were found between islet autoantibody positive and negative children and no relationship between responses to rubella and TT were found for individual children (data not shown).
Discussion
This study investigated the responses to vaccine antigens in young children with increased genetic risk for Type I diabetes in relation to autoantibody development. It is unique in that vaccination and appearance of islet autoimmunity can be related to each other, something which cannot be done in cross-sectional comparisons of patient and control populations of older subjects. The study shows that antibody responses to TT are generally characterized by early IgG1 antibodies and the appearance of IgG4 and lesser IgG2 antibodies upon further immunisation. Children without islet autoantibodies characteristically had this type of response regardless of their HLA genotype, and this was similar to previous reports for TT [21, 22, 23] , and protein antigens such as ovalbumin [24] and keyhole limpet haemocyanin [25, 26] . Children who had islet autoimmunity by one year of age did not have the shift to IgG4 and IgG2 anti-TT after booster vaccination, and consequently had predominantly undetectable or IgG1 restricted responses. This defect was independent of HLA class II genotype. In contrast, children who did not have islet autoantibodies at 9 months of age, but who developed them subsequently (and were therefore autoantibody negative at the time of vaccination), had relatively normal responses to TT which almost always included IgG4. The observation that reduced IgG2 and IgG4 responses to TT were found only in offspring who potentially had ongoing islet autoimmunity at the time of vaccination indicates that such a defect is either acquired, possibly a consequence of the islet autoimmunity, or inherently present in subjects who develop very early islet autoimmunity.
A reduced antibody response to vaccine bacterial antigens suggests either immune suppression or deviation. The reduction was most marked for IgG2 and IgG4 and seen only after booster vaccination, implying either a defect in the switching to, or production of, IgG2 and IgG4 upon immunisation with TT. IgG4 production is strongly promoted by IL-4 and IL-13 [27, 28] , and IL-10 further enhances IL-4 induced IgG4 production [29] .The strong correlation we observed between IgG2 and IgG4 anti-TT responses indicates that their production can be influenced by similar factors. Absent or low titres of both IgG2 and IgG4 are found in the antigen specific response of the IFNγ-dominated Lyme borreliosis disease [30] . IgG1 restricted responses are also seen in the IFNγ-dominant response to tuberculosis, whereas IgG2 antibod- ies are found in the IL-4-dominant response to leprosy [31] . All these support the concept that IgG4 immune responses are promoted by IL-4. Here, we also examined responses to rubella after vaccination with live attenuated virus in the BABYDIAB offspring. The response to this IFNγ inducing vaccine was relatively absent of IgG2 and IgG4 and heavily IgG1 dominated, further suggesting that the IgG4 response is not influenced by IFNγ. No differences were found in the subclass response to rubella in offspring with islet autoimmunity regardless of when autoantibodies appeared. This observation is consistent with a specific defect in IL-4 associated antibody responses to vaccine antigens in early pre-diabetes.
In order to relate the reduced antibody response to potential cytokine insufficiency at the T-cell level, we examined IgG subclasses of anti-TT and cytokine profiles of T-cell responses to TT. The T-cell responses included high IL-4 and IL-13 in some individuals, and remarkably, these individuals had much higher responses of IgG1, IgG2 and in particular IgG4 anti-TT, a finding consistent with a favouring of antibody responses in Th2 immunity, and with the reported IL-4 dependency of IgG4 production [13, 14, 15, 16] .
In conclusion, we have shown an impairment in the ability to produce the IL-4 related IgG4 antibody response to TT after booster vaccination in individuals who develop islet autoimmunity before 1 year of age. We found IgG4 responses to be a characteristic of antibodies to TT, but virtually absent after vaccination with live attenuated rubella virus, suggesting a Th2 cytokine dependency. Moreover, IgG4 responses were strongly associated with T-cell IL-4 and IL-13 production following stimulation with TT. We suggest that such a defect could be overcome with sustained exposure to antigen because patients with Type I diabetes can readily produce IgG4 antibodies to exogenous insulin [32] . Finally, an IL-4 dependent immune bias would be consistent with recent studies showing reduced number and function of IL-4 secreting NK T cells very early in NOD mice and humans with Type I diabetes [4, 5, 33] .
